Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Hagemann

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Plos One|August 1, 2014
Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxisUrs B Hagemann, Lavinia Gunnarsson, Solène Géraudie, et al.
Oncotarget|September 17, 2017
Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in <i>in vitro</i> and <i>in vivo</i> models of renal cell carcinomaUrs B Hagemann, Dessislava Mihaylova, Steinar R Uran, et al.
Biomacromolecules|July 30, 2014
Analysis of selected and designed chimeric D- and L-α-helix assembliesTim Kükenshöner, Urs B Hagemann, Daniel Wohlwend, et al.
Oncotarget|October 23, 2018
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer modelsMaria Quanz, Urs B Hagemann, Sabine Zitzmann-Kolbe, et al.
Frontiers in Medicine|February 2, 2023
Targeted thorium-227 conjugates as treatment options in oncologyJenny Karlsson, Christoph A Schatz, Antje M Wengner, et al.
Molecular Cancer Therapeutics|August 19, 2016
In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid LeukemiaUrs B Hagemann, Katrine Wickstroem, Ellen Wang, et al.
International Journal of Molecular Sciences|January 8, 2025
Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer ModelsUrs B Hagemann, Christoph A Schatz, Mari I Suominen, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|October 22, 2023
The trajectory of anti-recEm18 antibody levels determines follow-up after curative resection of hepatic alveolar echinococcosisSeverin Gloor, Wanjie Jiang, Martin H Maurer, et al.
Pharmaceuticals (Basel, Switzerland)|October 18, 2019
Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft ModelKatrine Wickstroem, Jenny Karlsson, Christine Ellingsen, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2020
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha TherapyUrs B Hagemann, Katrine Wickstroem, Stefanie Hammer, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Plos One|August 1, 2014
Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxisUrs B Hagemann, Lavinia Gunnarsson, Solène Géraudie, et al.
Oncotarget|September 17, 2017
Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in <i>in vitro</i> and <i>in vivo</i> models of renal cell carcinomaUrs B Hagemann, Dessislava Mihaylova, Steinar R Uran, et al.
Biomacromolecules|July 30, 2014
Analysis of selected and designed chimeric D- and L-α-helix assembliesTim Kükenshöner, Urs B Hagemann, Daniel Wohlwend, et al.
Oncotarget|October 23, 2018
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer modelsMaria Quanz, Urs B Hagemann, Sabine Zitzmann-Kolbe, et al.
Frontiers in Medicine|February 2, 2023
Targeted thorium-227 conjugates as treatment options in oncologyJenny Karlsson, Christoph A Schatz, Antje M Wengner, et al.
Molecular Cancer Therapeutics|August 19, 2016
In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid LeukemiaUrs B Hagemann, Katrine Wickstroem, Ellen Wang, et al.
International Journal of Molecular Sciences|January 8, 2025
Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer ModelsUrs B Hagemann, Christoph A Schatz, Mari I Suominen, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|October 22, 2023
The trajectory of anti-recEm18 antibody levels determines follow-up after curative resection of hepatic alveolar echinococcosisSeverin Gloor, Wanjie Jiang, Martin H Maurer, et al.
Pharmaceuticals (Basel, Switzerland)|October 18, 2019
Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft ModelKatrine Wickstroem, Jenny Karlsson, Christine Ellingsen, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2020
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha TherapyUrs B Hagemann, Katrine Wickstroem, Stefanie Hammer, et al.
Pageof 4